Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen, China.
Clin Respir J. 2024 Oct;18(10):e70023. doi: 10.1111/crj.70023.
The role of solute carrier family 35 member F3 (SLC35F3) in lung adenocarcinoma (LUAD) remains unclear. To address this gap, we conducted a study employing bioinformatics analysis and experimental validation.
This study aimed to examine the expression patterns of SLC35F3 in various cancer types, particularly focusing on LUAD, by analyzing data from the Cancer Genome Atlas (TCGA) database to evaluate its clinical relevance. The research also explored potential regulatory mechanisms of SLC35F3, including its interactions with immune infiltration, tumor mutational burden (TMB), and drug sensitivity in LUAD. The investigation included analyzing SLC35F3 expression in single-cell sequencing of LUAD cells, examining genetic variations of SLC35F3 in LUAD, and assessing SLC35F3 expression in cell lines using quantitative real-time PCR (qRT-PCR).
The aberrant expression of SLC35F3 was observed in both pan-cancer and LUAD. In LUAD patients, a statistically significant increase in SLC35F3 expression was correlated with gender (p < 0.001) and was associated with poorer overall survival (OS) (p = 0.020). The expression of SLC35F3 was identified as an independent prognostic determinant in patients with LUAD (p = 0.032). SLC35F3 exhibited associations with various pathways, including cell cycle and more. SLC35F3 expression demonstrated correlations with immune infiltration, TMB, and some drugs in LUAD. Results indicated significant upregulation of SLC35F3 in both LUAD tissues and cell lines.
SLC35F3 may serve as a prognostic biomarker and immunotherapeutic target for patients with LUAD.
Not applicable.
溶质载体家族 35 成员 F3（SLC35F3）在肺腺癌（LUAD）中的作用尚不清楚。为了解决这一差距，我们进行了一项研究，采用生物信息学分析和实验验证。
本研究旨在通过分析癌症基因组图谱（TCGA）数据库中的数据，研究 SLC35F3 在各种癌症类型中的表达模式，特别是聚焦于 LUAD，以评估其临床相关性。研究还探讨了 SLC35F3 的潜在调节机制，包括其与免疫浸润、肿瘤突变负担（TMB）和 LUAD 药物敏感性的相互作用。该研究包括分析 LUAD 细胞单细胞测序中的 SLC35F3 表达，检查 LUAD 中 SLC35F3 的遗传变异，并使用定量实时 PCR（qRT-PCR）评估 SLC35F3 在细胞系中的表达。
SLC35F3 的异常表达在泛癌和 LUAD 中均有观察到。在 LUAD 患者中，SLC35F3 表达的统计学显著增加与性别相关（p<0.001），与总生存期（OS）较差相关（p=0.020）。SLC35F3 表达被确定为 LUAD 患者的独立预后决定因素（p=0.032）。SLC35F3 与包括细胞周期在内的多种途径有关。SLC35F3 的表达与 LUAD 中的免疫浸润、TMB 和一些药物相关。结果表明 SLC35F3 在 LUAD 组织和细胞系中均有显著上调。
SLC35F3 可能作为 LUAD 患者的预后生物标志物和免疫治疗靶标。
不适用。
